Navigation Links
PET/CT Brings New Hope to Patients With Deadly Form of Breast Cancer
Date:11/27/2007

onic images will be available online at RSNA.org/press07 beginning Monday, Nov. 26.

RSNA is an association of more than 41,000 radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. The Society is based in Oak Brook, Ill. (RSNA.org)

Editor's note: The data in these releases may differ from those in the printed abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting. To ensure you are using the most up-to-date information, please call the RSNA Newsroom at 1-312-949-3233.

AT A GLANCE

-- Inflammatory breast cancer is a rare but aggressive form of breast

cancer that affects women at a younger age and spreads quickly

throughout the body.

-- The disease is characterized by redness, swelling or warmth in the

breast.

-- FDG-PET/CT accurately identifies inflammatory breast cancer metastases

early in the disease process, so treatment can be more effective.


'/>"/>
SOURCE Radiological Society of North America
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. 18F-DG PET/CT can highly increase the detection of colorectal cancer
2. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
3. Naked Juice Brings Consumers Happiness by the Billions With First 100% Juice Smoothie Containing Probiotics
4. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
5. PSI Brings its Pioneering Efforts to a Close
6. Serta Brings Sweet Dreams and a Special Delivery to Deserving Women
7. Eclipsys User Network Brings Eclipsys Clients Together to Share Outcome Improvement Strategies
8. Governor Rendell Brings Tour to Insure to Scranton and Urges Passage of Plan to Give Access to Affordable Health Insurance
9. New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs
10. IncentOnes Sue Lewis brings "The Art and Science of Incentive Management" to AHIP Business Forum
11. American Diabetes Month(R) Brings Awareness to Growing Health Care Crisis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ONTO, Jan. 8 /PRNewswire-FirstCall/ - Med-Emerg In... Canada,s leading providers of health services, is...ted in favour of the previously announced plan of ...oup Inc. ("AIM") at a special meeting of MedEmerg,... 90% of the votes cast at the meeting were in favo...
(Date:1/8/2009)...XANDRIA, Va., Jan. 8 To...nization along with several national leadership or... the principles of hospice care and protection of ...anding together in sharing this unified message ab...of Hospice and Palliative Medicine, Hospice and Pa...
(Date:1/8/2009)...ifornia Assembly Member Tom Torlakson Introduces A...-USNewswire/ -- Today, Lung Cancer Alliance-Cali... Tom Torlakson (D-11th District) for his continued...unding for lung cancer research. For the third co...ancer research is being considered in the Californ...
(Date:1/8/2009)...says it lowered bad cholesterol more effectively t...y News) -- After nearly a year of review, U.S. hea...e continued use of the controversial cholesterol-l...Administration said there was no significant diffe... taking Vytorin and patients taking the drug Zocor...
Breaking Medicine News(10 mins):Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2
... walk and stick to healthy food. That is a far mor... a group of US scientists has said.// In fact pr...tified when lifestyle changes are just as effectiv...osiglitazone pills do work, but so does weight los...
...ch has shown a way for people suffering diabetic r...arding as well as alleviating the effects of diabe... consequence of diabetes. In the initial stages, ...le symptoms but is capable of progressing graduall...
... outcomes for blacks with cardiovascular disease a...ferences in access and treatment are minimized, ac...rt Journal, Reuters reports. For the study, Nanc...emorial Veterans Hospital and colleagues studied t...
...w of the massacre that took place last week at the...iversity officials are asking the congressmen to f...isaster. Some kind of program, to identify and tre... and the others. A law that would permit the unive...
Other Medicine News:Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2Health News:Measures Needed to Avert Another Bloodbath 2
(Date:1/8/2009)...ated at the initial dose in an ongoing Phase Ib tr...line after three days , , Conference Call Today...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...st cohort of an ongoing Phase Ib clinical trial of...ide polymerase inhibitor. ANA598 was very well-to...
(Date:1/7/2009)...n., Jan. 7 Scientists h...high likelihood of relapse in children with acute ...hers caution that further research is needed to de... IKAROS, lead to leukemia relapse, the findings ...tic tests to assess the risk of treatment failure....
(Date:1/7/2009)...d., Jan. 7 ImQuest Life Sciences a... application to the Food and Drug Administration t...rimidinedione HIV inhibitor IQP-0410. ImQuest anti...rst quarter of 2009. IQP-0410 is a novel small mol...onnucleoside reverse transcriptase inhibitor (NNRT...
(Date:1/7/2009).... 7 Tiantan Puhua Hospital Stem Ce...worldwide leader in using stem cells to effectivel...x new globally experienced additions to its medica... hospital,s treatment capabilities for growing num...enior doctors include the distinguished Dr. Jiang ...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Continuous Blood Pressure Monitoring Predicts Risks 30515 1Continuous Blood Pressure Monitoring Predicts Risks 30515 2Continuous Blood Pressure Monitoring Predicts Risks 30515 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 111 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 211 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 411 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 511 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 611 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 7Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 1Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 2Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 1Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 2
...3, 2007 - Affymax, Inc.,(Nasdaq:AFFY) today announ...ical trials of Hematide(TM) in dialysis and,non-di...data showed,that in treatment naive, non-dialysis ...stered monthly at an appropriate dose.,Similarly, ...ith,three-times weekly Epoetin Alfa demonstrated t...
...7 - CytRx Corporation,(NASDAQ:CYTR) today announce...logy exclusively licensed to its majority-owned,su...as been,published in the April 2007 issue of peer-...The technology was developed by RXi,Co-founder, Sc...assachusetts Medical School (UMMS) Professor of Bi...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches.
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches.
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches.
Medicine Products: